Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy

MT Newswires Live

Jul 16

Molecular Partners (MOLN) said Thursday the first patients have been dosed in phase 2 study evaluating its experimental therapy, MP0317, in combination with chemoimmunotherapy as a first-line treatment for advanced biliary tract cancer, or cholangiocarcinoma.

The company said the study in France plans to enroll 75 patients to compare MP0317 plus standard-of-care treatment, including AstraZeneca's durvalumab and gemcitabine-cisplatin chemotherapy, with standard care alone.

The company expects a data update in 2027 and study completion in 2028, it added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2651414545"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651414545\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651414545?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 15:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651414545","market":"nz","top_or_hot":-1,"title":"Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy","media":"MT Newswires Live","content":"<html><body><p> Molecular Partners (MOLN) said Thursday the first patients have been dosed in phase 2 study evaluating its experimental therapy, MP0317, in combination with chemoimmunotherapy as a first-line treatment for advanced biliary tract cancer, or cholangiocarcinoma.</p><p>The company said the study in France plans to enroll 75 patients to compare MP0317 plus standard-of-care treatment, including AstraZeneca's durvalumab and gemcitabine-cisplatin chemotherapy, with standard care alone.</p><p>The company expects a data update in 2027 and study completion in 2028, it added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMolecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-16 15:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Molecular Partners (MOLN) said Thursday the first patients have been dosed in phase 2 study evaluating its experimental therapy, MP0317, in combination with chemoimmunotherapy as a first-line treatment for advanced biliary tract cancer, or cholangiocarcinoma.</p><p>The company said the study in France plans to enroll 75 patients to compare MP0317 plus standard-of-care treatment, including AstraZeneca's durvalumab and gemcitabine-cisplatin chemotherapy, with standard care alone.</p><p>The company expects a data update in 2027 and study completion in 2028, it added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MOLN","symbol_name":"Molecular Partners AG","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651414545","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651414545","pubTimestamp":1784187260,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Molecular Partners (MOLN) said Thursday the first patients have been dosed in phase 2 study evaluating its experimental therapy, MP0317, in combination with chemoimmunotherapy as a first-line treatmen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MOLN":"Molecular Partners AG","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"分子合作伙伴为胆道癌治疗 2 期研究中的首批患者注射剂量","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MOLN":1},"content_text":"Molecular Partners (MOLN) said Thursday the first patients have been dosed in phase 2 study evaluating its experimental therapy, MP0317, in combination with chemoimmunotherapy as a first-line treatment for advanced biliary tract cancer, or cholangiocarcinoma.The company said the study in France plans to enroll 75 patients to compare MP0317 plus standard-of-care treatment, including AstraZeneca's durvalumab and gemcitabine-cisplatin chemotherapy, with standard care alone.The company expects a data update in 2027 and study completion in 2028, it added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}